Wolfschlag et al. (2025). npj Parkinson s Disease. doi: 10.1038/s41531-025-00996-z
…analysis. For quantifying the extent of striatal dopaminergic denervation and counting of pS6 + cells, bright-field immunohistochemistry was performed using a primary antibody against TH (rabbit anti-TH, Pel-Freez P40101, 1:1000) and phosphorylated pS6, respectively (monoclonal rabbit anti Ser235/236-phospho-S6, Cell Signaling #2211, 1:200). Immunocomplexes were revealed using biotinylated secondary antibodies…
Pel-Freez products cited: Rabbit Anti-Tyrosine Hydroxylase (P40101)
Abstract
Abstract Dopamine replacement therapy for Parkinson’s disease can induce impulsive-compulsive behaviours (ICBs). Here we compare the D2/3 agonist ropinirole and L-DOPA, given alone or combined, with regard to their potential to induce ICBs in rats sustaining bilateral striatal injections of 6-hydroxydopamine. Daily treatment with ropinirole (2.5 mg/kg), L-DOPA (24.0 mg/kg), or their combination was given for six weeks while animals were examined using tests of compulsive checking and motor stereotypies not previously used in the ICB literature. Independently of L-DOPA cotreatment, ropinirole induced a stereotyped hyperactivity pattern, compulsive checking, and maladaptive choices in the rat version of the Iowa gambling task. Compared to both L-DOPA and vehicle, ropinirole elicited a distinct pattern of striatal neuroactivity, shifting the expression of a cellular activity marker from dorsolateral to centro-medial regions. Our results reveal quite distinct profiles of ICBs and striatal activation upon treatment with ropinirole or L-DOPA, providing clues of therapeutic relevance to Parkinson’s ICBs.